LONDON, March 6, 2017 /PRNewswire/ --
Norgine B.V. announced today that it has entered into an agreement with Noventure S.L., under which Norgine will distribute GELSECTAN(R) in Spain, Portugal and Andorra.
GELSECTAN(R) is a Class IIa CE marked medical device used as a treatment for irritable bowel syndrome (IBS) with diarrhoea. Diarrhoea is one of the symptoms often associated with irritable bowel syndrome. GELSECTAN(R) is available in capsules for oral use.
IBS affects up to 7.8% of the total Iberian population (Spain, Portugal and Andorra) and more than 100,000 new cases are reported every year.[i] Women are twice likely as men to develop IBS.[ii]
Peter Martin, COO at Norgine said: "We are delighted to be able to offer GELSECTAN(R), a new treatment option to patients who suffer from irritable bowel syndrome (IBS) associated with diarrhoea, a condition which can have a significant impact on quality of life."
He added: "This recent partnership demonstrates our commitment to sell further specialised innovative products through our well established infrastructure."
Luciano Conde, CEO of Noventure, said: "GELSECTAN(R) is an innovative product that will help to improve the lives of patients across the Iberian Peninsula. We are delighted to partner with Norgine, a recognised leader in the treatment of gastrointestinal diseases with a well-established presence in Spain and Portugal."
Norgine anticipates launching GELSECTAN(R) in Iberia in the second half of 2017. Noventure will manufacture GELSECTAN(R).
Financial terms are not disclosed.
Access full media release on http://www.norgine.com
i. Miguel a Montoro. Gastroenterologia y hepatologia. Problemas comunes en la practica clinica. 2012
ii. Mearin et al. Med Clin (Barc.) 2007; 128 (9):335-43
Norgine Media Contacts: